History

La Jolla NanoMedical was founded by a seasoned medical product development team to address a medical condition that affects millions of Americans every year.  Skin cancer is common, and it is only becoming more prevalent.

• La Jolla NanoMedical (LJNM) is addressing an important unmet need in a $1.78 Billion annual US market
• The technology applies bio-inert nanoparticles and infrared light to eradicate skin cancer tumors
• LJNM management team has successfully led and exited multiple medical companies previously
• LJNM is developing a novel medical device, with a predictable approval pathway